SANN Stock Overview
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Santhera Pharmaceuticals Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF9.50 |
| 52 Week High | CHF14.62 |
| 52 Week Low | CHF6.04 |
| Beta | 0.15 |
| 1 Month Change | -2.86% |
| 3 Month Change | -1.66% |
| 1 Year Change | 50.79% |
| 3 Year Change | -63.88% |
| 5 Year Change | -93.52% |
| Change since IPO | -98.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 1.4% | -8.0% | 0.03% |
| 1Y | 50.8% | 3.9% | -3.3% |
Return vs Industry: SANN exceeded the Swiss Biotechs industry which returned 5.5% over the past year.
Return vs Market: SANN exceeded the Swiss Market which returned -2.5% over the past year.
Price Volatility
| SANN volatility | |
|---|---|
| SANN Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: SANN has not had significant price volatility in the past 3 months.
Volatility Over Time: SANN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 46 | Dario Eklund | www.santhera.com |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company’s lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies.
Santhera Pharmaceuticals Holding AG Fundamentals Summary
| SANN fundamental statistics | |
|---|---|
| Market cap | CHF87.54m |
| Earnings (TTM) | -CHF4.95m |
| Revenue (TTM) | CHF54.27m |
1.6x
P/S Ratio-17.7x
P/E RatioIs SANN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANN income statement (TTM) | |
|---|---|
| Revenue | CHF54.27m |
| Cost of Revenue | CHF3.44m |
| Gross Profit | CHF50.83m |
| Other Expenses | CHF55.78m |
| Earnings | -CHF4.95m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 31, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 93.66% |
| Net Profit Margin | -9.13% |
| Debt/Equity Ratio | -94.9% |
How did SANN perform over the long term?
See historical performance and comparison